Oscar Health: A Misunderstood Platform
Oscar generated $328.8 million in Q1 adjusted EBITDA with a 9.8% operating margin, up 110 bps year-over-year. SG&A ratio fell to 15.8%, driven by 40% fixed-cost leverage and 15% tech-driven efficiencies like 98% auto-claims processing. A 5-year DCF with 30% FCF growth and a 5x terminal multiple supports a $61/share fair value, over 3x upside.
Oscar Health: Building The Operating System Of American Healthcare
Oscar Health's tech-driven flywheel is shrinking costs, boosting retention, and driving rapid membership growth, validated by 42% revenue growth and record profitability in Q1 2025. Platform revenue from +Oscar and data licensing is compounding faster than insurance premiums, creating a high-margin, SaaS-like earnings stream that legacy insurers can't match. Favorable policy trends and employer adoption of ICHRAs funnel incremental lives to Oscar at low acquisition cost, while Oscar's consumer-centric UX and provider partnerships deepen its moat.
Oscar Health, Inc. (OSCR) Stock Sinks As Market Gains: Here's Why
In the latest trading session, Oscar Health, Inc. (OSCR) closed at $20.42, marking a -3.77% move from the previous day.
Still Cheap After Near 100% Gains? Oscar Health Stock Could Continue Higher
Oscar Health, Inc. is undervalued despite a recent rally, with strong growth and earnings potential as a tech-driven disruptor in health insurance. The company boasts accelerating revenues, improving profitability, a robust balance sheet, and positive cash flow, supporting further upside. ACA enrollment growth, favorable ICHRA trends, and industry disruption position Oscar for continued success and margin expansion.
Oscar Health: I'm Bullish, But I'm Careful
Oscar Health is uniquely undervalued, combining 42% revenue growth with profitability and a low EV/Sales multiple, making it a standout in the market. The company's $2.23B cash position versus its $4.8B market cap highlights significant balance sheet strength and downside protection. ICHRA market expansion offers massive upside potential, but regulatory risks and limited pricing power cap long-term sustainability.
Oscar Health (OSCR) Soars 7.8%: Is Further Upside Left in the Stock?
Oscar Health (OSCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Oscar Health Could Be The Next Growth Monster With Tremendous Upside
Oscar Health is leveraging technology and AI to disrupt the health insurance industry, driving strong membership growth and improving operational efficiency. Financials are rapidly improving: premium revenue growth outpaces claims, margins are expanding, and the company has turned profitable with a strong balance sheet. Analysts project massive EPS growth through 2027, making OSCR undervalued compared to peers and offering significant upside for risk-tolerant investors.
Oscar Health, Inc. (OSCR) Laps the Stock Market: Here's Why
Oscar Health, Inc. (OSCR) reached $14.34 at the closing of the latest trading day, reflecting a +1.34% change compared to its last close.
Oscar Health: Steep Budget Cuts In 2026 Healthcare Estimates Spell Uncertainty
I rate Oscar Health as a Hold, due to proposed steep budget cuts in the 2026 budget, impacting Medicaid and Medicare Advantage coverage. Oscar Health's impressive financials and revenue growth are overshadowed by macroeconomic risks, including potential policy changes and increased uninsured rates. Despite strong internal operations and a projected revenue CAGR of ~20% between 2024 and 2027, external factors pose significant risks to growth.
Oscar Health, Inc. (OSCR) Q1 2025 Earnings Call Transcript
Oscar Health, Inc. (NYSE:OSCR ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Chris Potochar - Vice President of Treasury and Investor Relations Mark Bertolini - Chief Executive Officer Scott Blackley - Chief Financial Officer Conference Call Participants John Ransom - Raymond James Stephen Baxter - Wells Fargo Jonathan Yong - UBS Joanna Gajuk - Bank of America Josh Raskin - Nephron Research Jessica Tassan - Piper Sandler Michael Ha - Baird David Windley - Jefferies Operator Good morning, everyone. My name is Ellie, and I will be your conference operator for today.
Oscar Health, Inc. (OSCR) Beats Q1 Earnings and Revenue Estimates
Oscar Health, Inc. (OSCR) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.62 per share a year ago.
Oscar Health, Inc. (OSCR) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Oscar Health, Inc. (OSCR) stood at $13.01, denoting a -1.06% change from the preceding trading day.
